MEDBOT™

Shanghai MicroPort MedBot (Group) Co., Ltd.
上海微创医疗机器人(集团)股份有限公司
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2252)

CONNECTED TRANSACTION IN RELATION TO THE TERMINATION OF THE FINANCE LEASE AGREEMENT

TERMINATION OF THE FINANCE LEASE AGREEMENT

On 27 August 2026, Navibot Suzhou, a subsidiary directly owned as to 98% by the Company, entered into a termination agreement (i.e. the Termination Agreement) with Tianniuyan in respect of the Original Transfer Contract and the Original Finance Lease Agreement, pursuant to which (i) Navibot Suzhou agreed to pay Tianniuyan RMB20,917,835.15 (based on the outstanding principal lease amount and lease interest under the Original Finance Lease Agreement as at the date of the Termination Agreement and after deducting the deposit) (the "**Settlement Amount**"); and (ii) upon receipt of the Settlement Amount by Tianniuyan, Tianniuyan will transfer the ownership of the Prototypes to Navibot Suzhou, and the parties will no longer be entitled to any rights or bear any obligations under the Original Finance Lease Agreement.

LISTING RULES IMPLICATIONS

As at the date of this announcement, MicroPort is one of the controlling shareholders of the Company, and Tianniuyan is a wholly-owned subsidiary indirectly held by MicroPort. Therefore, it is a connected person of the Company under the Listing Rules. Accordingly, the transactions under the Termination Agreement constitute connected transactions for the Company under Chapter 14A of the Listing Rules.

Reference is made to the announcement of Shanghai MicroPort MedBot (Group) Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") dated 25 June 2024 (the "**Announcement**") in relation to the connected transactions involving Navibot Suzhou, as the lessee, entering into the Original Transfer Contract and the Original Finance Lease Agreement with Tianniuyan, as the lessor. Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement.

TERMINATION OF THE FINANCE LEASE AGREEMENT

The principal terms of the Original Finance Lease Agreement include: a total lease consideration of RMB66,000,000, comprising a principal lease amount of RMB60,000,000 and lease interest of RMB6,000,000, with a lease term of three years. As at the date of the Termination Agreement, the outstanding amount under the Original Finance Lease Agreement was RMB21,517,835.15, representing the aggregate of the outstanding principal lease amount and lease interest. After deducting the deposit of RMB600,000, the Settlement Amount was RMB20,917,835.15.

On 27 August 2026, Navibot Suzhou, a subsidiary of the Company, entered into the Termination Agreement with Tianniuyan in respect of the Original Transfer Contract and the Original Finance Lease Agreement, pursuant to which (i) Navibot Suzhou agreed to pay Tianniuyan RMB20,917,835.15; and (ii) upon receipt of the Settlement Amount by Tianniuyan, Tianniuyan will transfer the ownership of the Prototypes to Navibot Suzhou, and the parties will no longer be entitled to any rights or bear any obligations under the Original Finance Lease Agreement.

REASONS FOR AND BENEFITS OF ENTERING INTO THE TERMINATION AGREEMENT

The Termination Agreement will enable the Group to reduce interest expenses in future periods, lower overall financing costs, optimise debt structure, improve the Company's profitability and enhance the efficiency of fund utilisation, which is consistent with the Company's operational and financial management objectives.

The Termination Agreement is entered into by mutual agreement between Navibot Suzhou and Tianniuyan. The terms of the Termination Agreement are agreed after arm's length negotiations between the parties on normal commercial terms.

As the Termination Agreement is entered into in the ordinary and usual course of business of the Group on normal commercial terms, the Directors consider that the terms of the Termination Agreement are fair and reasonable, and are in the interests of the Company and the Shareholders as a whole.

Dr. Zhaohua Chang, a non-executive Director, together with Dr. Guoen Liu and Mr. Jonathan H. Chou, the independent non-executive Directors, also serve as directors of MicroPort and have therefore abstained from voting on the relevant Board resolutions of the Company. Apart from Dr. Zhaohua Chang, Dr. Guoen Liu and Mr. Jonathan H. Chou, none of the Directors has or is deemed to have a material interest in the Termination Agreement and the transactions contemplated thereunder and is required to abstain from voting on the relevant Board resolutions approving the Termination Agreement.

INFORMATION ON THE GROUP AND THE PARTIES TO THE TERMINATION AGREEMENT

The Group

The Group is principally engaged in designing, developing and commercialising surgical robots to assist surgeons in performing complex surgical procedures.

Navibot Suzhou

Navibot Suzhou, a company incorporated in the PRC with limited liability, a subsidiary which is directly held as to 98% by the Company, is principally engaged in the research, development and commercialisation of orthopaedic surgical robots of the Group.

Tianniuyan

Tianniuyan is a limited liability company established in the PRC and an indirect wholly-owned subsidiary of MicroPort. Tianniuyan is principally engaged in financial leasing business.

LISTING RULES IMPLICATIONS

As at the date of this announcement, MicroPort is one of the controlling shareholders of the Company, and Tianniuyan is a wholly-owned subsidiary indirectly held by MicroPort. Therefore, it is a connected person of the Company under the Listing Rules. Accordingly, the transactions under the Termination Agreement constitute connected transactions for the Company under Chapter 14A of the Listing Rules.

DEFINITIONS

In this announcement, the following expressions shall have the meaning set out below unless the context requires otherwise:

"Board"	the board of Directors
"Company"	Shanghai MicroPort MedBot (Group) Co., Ltd. (上海微创医疗机器人(集团)股份有限公司), a joint stock company incorporated in the PRC with limited liability, the H Shares of which are listed on the main board of the Stock Exchange (Stock Code: 02252)
"connected person"	has the meaning ascribed thereto under the Listing Rules
"Director(s)"	director(s) of the Company
"Group"	the Company and its subsidiaries
"Listing Rules"	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited
"MicroPort"	MicroPort Scientific Corporation (微創醫療科學有限公司), an exempted company incorporated in the Cayman Islands with limited liability whose shares are listed on the main board of the Stock Exchange (stock code: 00853), and one of the controlling shareholders of the Company
"Navibot Suzhou"	MicroPort NaviBot (Suzhou) Co., Ltd. (蘇州微創暢行機器人有限公司), a company incorporated in the PRC with limited liability and a subsidiary which is directly held as to 98% by the Company
"Original Finance Lease Agreement"	the finance lease agreement entered into between Navibot Suzhou and Tianniuyan on 25 June 2024
"Original Transfer Contract"	the transfer contract entered into between Navibot Suzhou and Tianniuyan on 25 June 2024
"PRC" or "China"	the People's Republic of China, but for the purpose of this announcement, shall exclude the Hong Kong Special Administrative Region of the PRC, the Macau Special Administrative Region of the PRC and Taiwan

"Prototypes"	a total of 27 prototypes for the orthopaedic surgery navigation positioning system and other selected hard tissue surgery navigation positioning system
"RMB"	Renminbi, the lawful currency of the PRC
"Shareholder(s)"	the shareholder(s) of the Company
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"Termination Agreement"	the Termination Agreement entered into between Navibot Suzhou and Tianniuyan on 27 August 2026
"Tianniuyan"	Shanghai MicroPort Tianniuyan Financial Leasing Co., Ltd. (上海微創天牛眼融資租賃有限公司), a company incorporated in the PRC with limited liability and an indirect wholly-owned subsidiary of MicroPort

By order of the Board
Shanghai MicroPort MedBot (Group) Co., Ltd.
Dr. Zhaohua Chang
Chairman

Shanghai, China, 27 August 2026

As at the date of this announcement, the executive Director is Dr. Chao He, the non-executive Directors are Dr. Zhaohua Chang, Mr. Hiroshi Shirafuji, Mr. Norihiro Ashida, Mr. Chen Chen and Ms. Min Liang, and the independent non-executive Directors are Dr. Guoen Liu, Mr. Jonathan H. Chou, Mr. Haisong Yao and Mr. Wai Man Chung.